Diagnostics & Tools April 2022

Crosstree BlueBooks provide an executive review of key health sciences transactions, financial movements, and public market activity. BlueBooks also offer a glimpse of how valuations are changing and how recent trends may affect future transactions.

• Groupe Bruxelles Lambert (GBL) has agreed to acquire Affidea for approximately $1bb
• bioMérieux has agreed to acquire Specific Diagnostics for $391mm
• Castle Biosciences has acquired AltheaDx for $140mm